Exosomal miR‐423‐5p targets SUFU to promote cancer growth and metastasis and serves as a novel marker for gastric cancer

Exosomes are critically involved in tumor growth, metastasis, and therapy resistance. Exosomes have the potential to be utilized as cancer biomarkers. In this study, we aimed to explore the roles and clinical values of exosomal miRNAs in gastric cancer. We found that the concentration of exosomes was significantly higher in the serum of gastric cancer patients and the culture supernatants of gastric cancer cells than that in healthy volunteers and gastric mucosa epithelial cells. In particular, miR‐423‐5p was elevated in the serum exosomes of gastric cancer patients, and the level of exosomal miR‐423‐5p was remarkably correlated with lymph node metastasis. High level of exosomal miR‐423‐5p was associated with poor outcome in gastric cancer patients. MiR‐423‐5p enriched exosomes could be internalized into gastric cancer cells, which enhanced cell proliferation and migration both in vitro and in vivo. Mechanistically, miR‐423‐5p inhibited the expression of suppressor of fused protein (SUFU) to enhance the proliferation and migration of gastric cancer cells. The expression levels of SUFU were significantly decreased in gastric cancer cells and the tumor tissues of gastric cancer patients. Taken together, our findings indicate that exosomes could deliver miR‐423‐5p to promote cancer growth and metastasis and serum exosomal miR‐423‐5p may serve as a potential marker for gastric cancer diagnosis and prognosis.